bluebird bio
Biotechnology company developing gene therapies for severe genetic diseases, including FDA-approved treatments for sickle cell disease and beta-thalassemia.
Website
https://www.bluebirdbio.comLocation
Somerville, Massachusetts, USA
Founded
2010
Investors
1
Categories
biotech, gene-therapy, rare-diseases, sickle-cell, beta-thalassemia, genetic-diseases
Notes
bluebird bio is a pioneering gene therapy company focused on developing transformative genetic medicines for severe genetic diseases. The company has achieved significant milestones including FDA approval of multiple gene therapies:
- LYFGENIA (lovotibeglogene autotemcel) - approved for sickle cell disease
- ZYNTEGLO (betibeglogene autotemcel) - approved for beta-thalassemia
These one-time gene therapies are designed to provide functional copies of defective genes, potentially freeing patients from the burden of chronic disease management and complications.
Team
- Andrew Obenshain - President and CEO
- Leadership team with extensive gene therapy and rare disease expertise
Additional Research Findings
- Publicly traded company
- Backed by ARCH Venture Partners
- FDA-approved gene therapies for sickle cell disease and beta-thalassemia
- Pioneer in lentiviral gene therapy
- Focus on severe genetic diseases
- One-time curative treatment approach
- Somerville, MA headquarters (Greater Boston area)
- Manufacturing and commercial infrastructure for gene therapies
Sources
- bluebird bio Official Website
- bluebird bio LinkedIn
- FDA drug approvals database
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| ARCH Venture Partners | Chicago, USA | biotech-focused | seedseries-a+3 | 6 |